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Abbreviations  
SD-WLE=Standard definition    white light endoscopy 
AFI=Autofluorescence imaging 
CD=Crohn’s disease 
CE=chromoendoscopy 
CLE=confocal laser endomicroscopy 
GMP=good manufacturing practice 
IBD=inflammatory bowel disease 
iCE=indigo carmine–aided chromoendoscopy 
iCLE=integrated confocal laser endomicroscopy 
IN=intraepithelial neoplasia 
mCE=methylene blue–aided chromoendoscopy 
ME=magnifying endoscopy 
NBI=narrow-band imaging 
pCLE=probe-based confocal laser endomicroscopy 
PSC=primary sclerosing cholangitis 
UC=ulcerative colitis 
BLI=Blue laser imaging  
LCI= Linked colour image  
VCE =Virtual electronic endoscopy 
SCENIC = international consensus statement on surveillance and management of dysplasia in inflammatory 
bowel disease 
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ABSTRACT 
Endoscopic assessment of inflammation and mucosal healing is crucial  for appropriate  management in IBD. 
Current definition of endoscopic mucosal healing have been derived using previous generation of standard 
white light endoscopes. New  endoscopy technologies widely available provide much more detailed images of 
mucosal and vascular patterns  
Novel endoscopic techniques  with high definition image, optical and digital  enhancement  have enhanced the 
quality and fine details of vascular and mucosal  pattern so that endoscopic images have started to reflect 
histologic changes for lesions and inflammation/healing . These technologies  can now define subtle 
inflammatory changes and increase detection and characterisation of colonic lesions in IBD patients. 
The best endoscopic technique to detect dysplasia in IBD is  still debated.  Dye chromoendoscopy with 
targeted biopsies is considered by SCENIC consensus guidelines the standard  of care and  recommended for 
adoption by  gastroenterologists in practice. In future it is possible that  well trained colonoscopists using HD 
equipment with image enhancements may be able to obtain equivalent yield without pan-colonic dye spraying 
and characterise lesions.  
Finally, SCENIC introduced endoscopic resectability of some dysplastic colonic lesions  -  new techniques, 
may now better characterise endoscopic resectability and limit the number of colectomies.   
In this review, we will provide a state of the art opinion on the direction of technological advances in the 
assessment of IBD and how new concepts will refine clinical practice. 
 
 Keywords : mucosal healing, ulcerative colitis  Crohn’s disease, intraepithelial neoplasia , , Novel 
endoscopic techniques, Dye chromoendoscopy ,Optical Enhancement, iScan, electronic virtual 
chromoendoscopy, Narrow banding image , Blue laser image  
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1. INTRODUCTION 
 
Endoscopic assessments of extension, grade of inflammation and mucosal healing (MH) as well as early 
detection of neoplastic colonic lesions are important key parameters for management of patients with 
inflammatory bowel disease (IBD). Indeed, mucosal and histological healing predicts sustained clinical and 
steroid free remission, and avoids complications, hospitalisation and surgery. There is an emerging strategy in 
some countries to consider stopping or de-escalating biological therapy in patients with IBD to reduce side 
effects and cost burden. Endoscopic MH is a key endpoint to achieve before considering exit strategy from 
targeted therapies. (1). In general, patients in clinical, biomarker, and endoscopic remission are more likely to 
remain well when treatment is de-escalated. However, there is still not an ideal validated definition of 
endoscopic MH in IBD. The current endoscopic scoring systems, used in the clinical practice, to assess 
severity of inflammation in IBD were not designed to reflect endoscopic features of MH.  They have some 
limitations, cannot detect and assess mild patchy inflammatory mucosal changes and differentiate well 
between quiescient and mild activity of the disease.  Importantly, most of these endoscopic scores have been 
developed with the previous generation standard white light endoscopes (WLE). (2) With the new advanced 
high definition (HD) endoscopic technologies, optical diagnosis Narrow Banding Imaging (NBI, Olympus 
Japan) Optical enhancement iSCAN (iSCAN –OE Pentax , Japan) ,  Blue Laser Image ( BLI , Fujifilm Japan) 
and Confocal Laser Endomicroscopy ( CLE, Mauna Kea France), endocytoscope ( Olympus ,Japan ) and the 
emerging endoscopic molecular labeling, modern endoscopy can  attain optical characterisation reflecting 
histology better. In Crohn’s disease, the need for a new consensus to define mucosal healing is clearly 
required as discussed in details as a viewpoint recently by Bossuyt et al (REF). It is still debated how 
surveillance should be optimally performed to increase the detection rate of colonic neoplasia  in patients with 
IBD and better characterise lesions.  Dye chromoendoscopy  (DCE) is considered the standard endoscopic 
technique following the SCENIC consensus statementsguidelines.  While DCE with targeted biopsies 
currently provides the best lesion detection yield in long standing UC, there is growing evidence that in future 
well trained colonoscopists using HD equipment with optical and digital enhancements may be able to obtain 
equivalent yield without pan-colonic dye spraying.(3). We discuss below how such new techniques, combined 
with new endoscopic advanced endoscopic resection techniques (mucosal and submucosal resection) promises 
to limit the number of colectomies in the presence of dysplasia. (4)  
We have not considered small bowel enteroscopy or video capsule enteroscopy in this review where advanced 
imaging technologies have not been widely applied.  We have not discussed advanced therapeutic procedures 
such as dilation of strictures but these have been discussed in recent references (REF Shen Bo) 
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2.CURRENT STATUS OF ENDOSCOPIC AND HISTOLOGICAL HEALING IN UC AND CD  
MH is an important therapeutic endpoint to achieve in IBD and is now widely accepted as a reliable target for 
optimum management of IBD patients (Selecting therapeutic targets in inflammatory bowel disease). 
STRIDE) (5). The terms MH and "deep remission"(clinical + endoscopic) are considered new therapeutic 
targets in the treatment of IBD patients.  MH is a term used interchangeably with endoscopic healing though 
in future these two terms may become more specific. (5)  
At present there is no clear endoscopic definition of MH when WLE is used, and the lower end of endoscopic 
inflammation assessment scale is considered de facto MH. In the clinical trials Mayo Endoscopic Score 
(MES) 0 and 1 are considered to represent MH, but 0 is better than 1 and should be the optimal goal to aim 
for. (6-8,18) 
Carvalho et al reported that in patients with left-sided or extensive colitis, MES 1 was associated with an 
increased risk of clinical relapse compared with MES 0 (27.3% versus 11.5% p= 0.022) as well as increased 
risk of steroids or immunosuppressant drugs and hospitalisation (13.0% versus 3.3% p=0.044. Clearly using 
MES 1 has limitations when considering MH.  (6) The time period for observation was at 12 months after 
total colonoscopy. 
The exact histological definition of MH continues to evolve and the most appropriate definition of histological 
remission has yet to be determined and currently is not considered as a target in UC (STRIDE) (5). However 
histological assessment in addition to HD white light colonoscopy is considered a sensitive measure of the 
absence of inflammation and there are evolving histological classifications being developed such as Robarts 
histological index (RHI) and NANCY histological score that aim to better define remission. (9,10).  
 
(A) Current Endoscopic scoring systems in UC and their limitations  
Several scoring systems have been developed using WLE some of which require further validation and 
noneall of these have not included the specific endoscopic features and definition of MH. The Mayo 
endoscopic score (MES) is the most commonly used in the clinical practice and trials and more recently other 
scoring systems have been developed and validated such as the Ulcerative Colitis Endoscopic  Index Severity 
(UCEIS) and The Ulcerative Colitis Colonoscopic Index of Severity (UCCIS). (11,12,13,18) Table 1 
 
Travis et al. proposed the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)  - based on WLE as a 
reliable and validated score of endoscopic severity in UC as an alternative to the MES. (12). UCEIS takes into 
account three endoscopic findings - vascular pattern, bleeding, and erosions/ulcers. It is a useful tool in 
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clinical practice and is starting to be adopted routinely in central readouts for clinical trials. However, it also 
has several limitations as the definition of MH and the threshold for mild to moderate and severe disease are 
not clearly described, the disease extension is not evaluated and advantage in the inter-observer agreement 
over MES has not yet been demonstrated. 
The Ulcerative Colitis Colonoscopic Index of Severity (UCCIS) was recently proposed to overcome these 
limitations and to include disease extension but is more complex,, has not been adopted in daily practice and 
is not validated in large studies yet. (13)  
Some of the components of these scores such as vascular pattern are now outdated as newer generation of 
endoscopes demonstrate abnormal vascular patterns rather than loss or obliterated vascular pattern and 
friability, in severe disease as well as in mild disease (12 13). Regenerative changes and scarring/drop out of 
pits have generally not been considered with WLE. Therefore there is a need for new or adapted endoscopic 
scoring systems that are relevant to the current generation of HD endoscopes equipped with electronic virtual 
chromoendoscopy (VCE).  
 
(B) Current endoscopic scoring systems in Crohn’s disease and their limitations  
In CD the inflammation is transmural and MH is considered as minimum goal for successful mucosal 
endpoint (STRIDE).(5)  The assessment of inflammation in CD requires multiple cross sectional radiological 
imaging (MR or CT enterography, preferably the former) and/or mucosal endoscopic evaluation to ensure 
complete healing after therapy (including enteroscopy). 
The most common endoscopic scoring indices are the CD Endoscopic Index of Severity (CDEIS) and the 
Simple Endoscopic Score for CD (SES-CD). (14,15) However, the operating characteristics in terms of 
validation, responsiveness and reliability of these endoscopic indices to assess inflammation and predict 
outcome in CD is not clear yet. Potential limitations of these endoscopic scores are that these do not include 
the definition of MH, and the complexity of calculation make these score difficult to be adopted in daily 
clinical practice. Recently Khanna et al have also assessed the responsiveness of the CDEIS and SES-CD 
using data from a trial of adalimumab. The SES-CD demonstrated numerically greater response to treatment 
and compared to CDEIS, stronger correlation with the global evaluation of lesion severity (GELS), and is less 
cumbersome to calculate. (16) However, the exact threshold of SES-CD to define response to therapy as 
endoscopic endpoint in clinical trials ,the general lack of clear definition of MH  and of adoption in clinical 
practice remain limitations.  
The Rutgeerts score for postoperative CD recurrence was developed 1990 by examining 89 patients with 
ileal resection for CD and observing clinical outcomes in patients with early neo-terminal ileum lesions. A 
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5-grade stepwise numeric ulcers index gradation of endoscopic postoperative recurrence in the neo-
terminal ileum were developed (17) Although the score has been adopted in both trials and clinical practice, 
only a few very recent studies have explored intra- and inter-observer agreement, but lack robust formal 
validation,  Another limitation of the Rutgeerts’ score is when the anastomosis cannot be reached and passed, 
the neo-terminal ileum cannot be assessed. Clear distinction between inflammatory and suture or ischaemic 
ulcers is difficult.  Further new  development and more detailed scoring systems are required in the future, 
especially as all the scores were defined using WLE only .(17) 
 
3.WHAT ARE THE NEW TECHNOLOGIES THAT ARE AVAILABLE 
Recent advances in endoscopic assessment in IBD include dye based Chromoendoscopy (DCE), Virtual 
Electronic Chromoendoscopy (VCE), Confocal Laser Endomicroscopy (CLE), and endocytoscopy which 
have dramatically improved visualisation of patchy  subtle mucosal changes  allowing targeted biopsies and 
increasing the yield  and characterisation of colonic dysplastic lesions in IBD. In addition, the image 
resolution of HD endoscopes is much improved compared to standard WLE. Thus novel endoscopy have 
started to show promise to approximate histologic readouts.  (19) 
 
(A).  High Definition & Dye Chromoendoscopy  
HD colonoscopy is an advanced technology employing a HD monitor and high resolution charge-coupled 
device (CCD). HD endoscopes produce image signals with resolution of 850,000 to 2 million pixels and offer 
a field of vision of 170°, instead of standard-definition (SD) which produces signal images with resolutions of 
100,000 to 400,000 pixels with a field of vision of 130°. 
The increased resolution of HD endoscope offers an opportunity for better characterisation and definition of 
the borders of neoplastic lesions in IBD patients.(20) 
DCE is an endoscopic technique which uses the topical application of stains to improve identification and 
characterisation of colonic  lesions during endoscopy. Common staining agents used are methylene blue as an 
absorptive contrast and indigo carmine as a reactive agent. (21) 
(B).Dyeless Chromoendoscopy  
 VCE includes optical technologies such as Narrow-Band Imaging (NBI, Olympus), Flexible Imaging Colour 
Enhancement (FICE, Fujinon) and I-Scan (Pentax) and can enhance details of tissue surface without any 
application of dye, as well as blood vessels. A direct image is obtained with the standard WLE, which uses the 
full visible wavelength range (400-700 nm) to produce a red-green-blue image, and with NBI, where optical 
filters are used to reflect the light. FICE and I-Scan methods are based on the reflection of photons to 
reconstruct virtual images, through a digital post-processing of the endoscopic images, without any filter 
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application. (22-25) 
Two new image-enhanced colonoscopes, using the LASEREO system (Fujifilm, Japan), have recently been 
developed: blue laser imaging (BLI) and linked colour imaging (LCI).  
The BLI system is equipped with a light source (LL-4450) and a processor (VP-4450HD) with two types of 
diode laser and it can be used for the examination of both the micro-vessels and the mucosa.  
The LCI expanded the colour range of reddish and whitish colours, therefore enhancing slight differences in 
the red region of the mucosa in conditions including inflammation and cancer.(23) 
The new i-Scan Optical Enhancement (OE) (Pentax, Japan) is a combination of optical and a digital 
enhancement chromoendoscopy in a single system. It consists of three different algorithms that can be 
selected by pressing a button on the endoscope: contrast enhancement (to digitally add blue colour to 
relatively dark areas), surface enhancement (to modify luminance intensity) and tone enhancement. (24) 
A novel endoscopic system and colonoscope with NBI capability and a “dual focus” function has recently 
been introduced. This enables dual-focus near-field magnification by pushing   a single button to closely 
examine the mucosal tissue and capillary network. (25) Currently many gastroenterologists are not utilising 
the full potential of such advanced technologies integrated in current generation of equipment. 
 
 
 
44. APPLICATIONS OF NEW TECHNOLOGIES THAT ARE AVAILABLE IN IBD 
 
(A) New paradigms to assess  endoscopic inflammation and healing  in IBD 
Recently, many studies have showed that HD in combination with VCE can precisely assess inflammatory 
activity and extension of IBD disease (8,26,28).  With the advanced VCE systems the vessels appear not 
absent or obliterated but irregular and distorted especially in mild and patchy inflammation.  
First ,Kudo et al  have  showed that NBI can contribute to the clear visualisation of Mucosal Vascular Pattern 
(MVPPV) in patient with UC(27). They have showed MVPMPV to be associated with the histological 
severity, especially regarding acute inflammation in patients with UC. NBI could  depict  vessels in the deep 
layer, which could  not be discerned by standard definition (SD)-WLE. The MVP under NBI comprises two 
distinctive patterns:  deep vasculature as depicted green in colour, and superficial vasculature which are brown 
in colour. There was a significant association with acute inflammatory cells (26% versus 0% p0.0001) and 
goblet cell deposition  (32% versus 5% p0.0006) in the segments with distorted MPVP.  However , NBI has 
some limitations to assess moderate /severe disease where intra-mucosal bleeding is a feature due to the 
absorption of light by haemoglobin, but there maybe a role in predicting relapse in patients with quiescent 
disease.(27). Hayashi et al have recently confirmed that that magnifying NBI observation of mucosa was  
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effective for the assessment of UC follow-up.  The endoscopic vascular pattern features were accurately 
assessed by NBI with magnification and were important predictors of UC relapse (28,29) The i-SCAN system 
has also showed promising results. Neumann et al have showed that  VCE significantly improves prediction 
of  inflammatory activity and extent with an agreement of 53.85% and 48.71% (p0.0009) in the HD WLE 
group and 89.74% and 92.31% in the VCE group (p 0.066). (30)  
We have developed the first VCE (i-SCAN) endoscopic scoring system to assess inflammation in UC and 
have introduced endoscopic findings of mucosal and vascular healing. (26) A new histological scoring system 
(ECAP system: Extent, Chronicity, Activity, Plus additional findings) was also designed to reflect chronic and 
acute histological changes in UC.  In patients with Mayo endoscopic sub-score of 0, 30.4 % had an abnormal 
mucosal pattern and 73.9 % of them had an abnormal vascular pattern on VCE. The VCE was able to pick up 
subtle histological abnormalities underlying the apparently healed mucosa in UC as assessed by the refined 
ECAP histology scoring system. (8)  
The PiCaSSO (Paddington International Virtual ChromoendoScopy ScOre) is a recent VCE scoring system in 
UC to redefine endoscopic findings of mucosal and vascular healing  developed by international experts in 
optical diagnosis. (19) The new PICaSSO embraced all the endoscopic findings of the inflammation in UC 
and performed better than the previous i-SCAN score developed by Iacucci et al. The interobserver agreement 
of the PICaSSO score between the experts was very good in the pre-test and post-test evaluations and the 
accuracy of the overall PICaSSO in assessing histologic abnormalities and inflammation by Harpaz score was 
57% (95% CI, 48%-65%), by RHI 72% (95% CI, 64%-79%), and by ECAP system  83% (95% CI, 76%-88%). 
(19) ( video) 
The PICaSSO SCORE  also  achieves good inter-rater agreement post-training, across all levels of endoscopy 
experience.  Correlation between PICaSSO and histology was strong, with performance accuracy that is 
sustainable over time. (31) Outcomes of mucosal healing defined by PICaSSO are being assessed in a 
multicentre study. The Mayo endoscopic score used MES 0 or 1 as definition of mucosal healing, but it is 
simply the lower end of the inflammation scoring system. The PICaSSO can define mucosal healing better 
with both mucosal and vascular healing and correlates with histologic scores better and a training module may 
improve performance (31).. 
 
Iacucci et al  have also recently reported the first experience on using the newly introduced i-scan Optical 
Enhancement (OE) with magnification (Pentax, Japan) to assess subtle  inflammatory changes in UC. The 
new OE i-scan endoscopic score correlate very well with histological ECAP (r = 0.70;P < 0.001). The 
accuracy of the I-SCAN OE score to detect abnormalities by ECAP was 80% (sensitivity 78%, specificity 100 
%).(28), the correlation between I-SCAN OE score and RHI was r=0.61 (P < 0.01), and the accuracy to detect 
abnormalities by RHI was 68% (sensitivity 78%, specificity 50%). (26) 
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The PICaSSO SCORE  also  achieves good inter-rater agreement post-training, across all levels of endoscopy 
experience.  Correlation between PICaSSO and histology was strong, with performance accuracy that is 
sustainable over time. (31) Outcomes of mucosal healing defined by PICaSSO are being assessed in a 
multicentre study. 
Recently, a novel imaging technique  developed by Fujifilm,Japan  is linked colour imaging (LCI). LCI  
vascular pattern classification was developed  to better assess inflammation and MH in UC. The LCI score 
strongly correlate with histology and interobserver agreement for LCI was excellent between experts and non 
experts. VCE and LCI may be a novel approach for evaluating colonic MH  and for predicting relapse  and  
outcome in UC patients  and guide monitoring and treatment decision( 32) 
Detailed	description	of	mucosal	healing	may	bridge	the	gap	between	endoscopic	and	histologic	
definitions	of	mucosal	healing.	In	UC	especially	histologic	healing	is	increasing	been	highlighted	as	
reflecting	long	term	outcome	better,	but	in	future	more	precise	endoscopic	definitions	of	mucosal	
healing	may	overcome	this 
 
 
 
(B) New paradigm to detect dysplasia in IBD 
In a retrospective cohort study in long-standing colonic IBD patients, HD colonoscopy was associated with a 
2-fold higher dysplasia detection rate on targeted biopsy when compared with SD WLE. Thirty-two dysplastic 
lesions (27 on targeted biopsy) were detected in 24 patients in the HD group and 11 dysplastic lesions (six on 
targeted biopsy) were detected in eight patients the SD group. (20) 
In 2003 Kiesslich et al  performed the first randomized controlled study of 263 patients with long standing UC 
(>8 years). The study assessed  inflammation extension and detection of intraepithelial neoplasia ( INs) in 
patients with UC using  DCE  with target biopsies  vs WLE. When using DCE they demonstrated an 
agreement between endoscopic prediction of extent of inflammation and histology of 84.5% versus 37% in 
those having routine WLE (p=0.0001). (33). DCE led to a significant 3.2-fold increase in the number of 
detected INs in UC as compared with WLE random biopsy sampling. However this technique is time-
consuming,  adds costs and while it is standard of care currently, it is likely to be challenged by newer 
technologies such as VCE in future. (34,3) 
Recently, SCENIC consensus guidelines recommended DCE with targeted biopsies as the optimal modality to 
be adopted in the daily practice to increase the detection colonic dysplasia in patient with IBD.  In the 
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SCENIC meta-analysis 8 studies were identified used DCE compared with WLE alone and revealed a 
significantly greater proportion of patients with dysplasia by using DCE (relative risk [RR] = 1.8 [1.2-2.6] and 
absolute risk increase  of 6% [3%-9%]).  (3, 33, 35-37). Based on a real life study, random biopsies should 
still be considered in association with DCE in patients with IBD with a personal history of neoplasia, 
concomitant PSC or a tubular colon during colonoscopy.(Moussata D et al 2018 38).  In SCENIC consensus 
unanimous agreement could not be reached on this question though 80% of the panellists favoured targeted 
biopsies only.  
 
 
The SCENIC meta-analysis has some limitations and has considered studies using the previous generation of 
endoscopes with standard WLE rather the new generation of the endoscopes with HD resolution of image.  
The use of the DCE has been limited mostly to low –quality observational studies and only two randomised 
controlled trials were conducted. Moreover, the SCENIC consensus did not recommend other endoscopic 
techniques such as VCE (NBI, iSCAN, BLI)  because  there were not yet evidence of their effectiveness in 
detecting dysplastic lesions in IBD patients  compared with DCE.(3) 
 
 
Recently, a multicentre prospective cohort study from Spain has confirmed the value of DCE in 350 long-
standing IBD patients undergoing surveillance colonoscopy using WLE followed by 0.4% indigo carmine 
DCE. Results showed a higher dysplasia miss rate with WLE, and 57.4% incremental yield for DCE. 
Detection rate of dysplasia was comparable between SD and HD colonoscopies (51.5% versus 52.3%, 
p=0.30). Moreover, dysplasia detection rate was comparable between expert and non-expert (18.5% versus 
13.1%, p=0.20) and no significant learning curve was observed (8.2% versus 14.2%, p=0.46). (38)  
However, the effectiveness of DCE for IBD surveillance is controversial and debated and there are still many 
barriers such as learning curve, cost and time as well as procedure reimbursement, are some of the main issues 
to resolve in order to facilitate and widely implement DCE in routine practice.  
 
The SCENIC meta-analysis has some limitations and has considered studies using the previous generation of 
endoscopes with standard WLE rather the new generation of the endoscopes with HD resolution of image.  
The use of the DCE has been limited mostly to low –quality observational studies and only two randomised 
controlled trials were conducted. Moreover, the SCENIC guidelines did not recommend other endoscopic 
techniques such as VCE (NBI, iSCAN, BLI)  because  there were not yet evidence of their effectiveness in 
detecting dysplastic lesions in IBD patients  compared with DCE.(3) 
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Initial studies for dysplasia detection had explored NBI as the first introduced VCE in clinical practice. In a 
prospective trial from Netherlands, NBI colonoscopy did not increase  the detection rate of dysplastic lesions 
in patients with longstanding UC. (39) A randomised cross-over trial confirmed the same results in patients 
with UC who underwent both NBI and HD colonoscopy within 3 weeks; of the 11 patients with neoplasia 
82% were diagnosed with HD colonoscopy versus 73% by NBI (p=1.0), suggesting that NBI does not 
significantly improve the detection of neoplasia. (40) Moreover, in the randomised study by Pellise et al 
comparing HD colonoscopy plus NBI with HD colonoscopy plus DCE, no significant difference was found in 
the detection rates of dysplasia between the two groups. In the NBI group, however, there was a higher miss 
rate of dysplastic lesions as compared to DCE. (41). Furthermore, in three trials which compared WLE and 
NBI colonoscopies,  there was no difference in dysplasia detection rate between the two procedures. [39-43]. 
Efthymiou et al have shown in a tandem colonoscopy trial that DCE is more sensitive than NBI in detecting 
lesions for target biopsy but that the overall detection of dysplasia was not different between NBI and DCE 
[44]. Based on these heterogeneous results in these trials SCENIC consensus guidelines have not 
recommended the use of VCE in the clinical practice. However, two recent randomised trial have revealed 
that these electronically enhanced procedures are  effective  in detecting neoplastic lesions also in patients 
with IBD. 
 
However, two recent randomised trial have revealed that these electronically enhanced procedures are  
effective  in detecting neoplastic lesions also in patients with IBD. 
Iacucci et al  have showed iSCAN VCE or HD-WLE  was not inferior to DCE for detection of colonic 
neoplastic lesions during surveillance colonoscopy. In fact, in this study HD-WLE alone was sufficient for 
detection of dysplasia, adenocarcinoma or all neoplastic lesions. (45) Bisschops et al evaluated whether NBI 
produced different results than DCE in patients with UC. In this international, multi-centre prospective 
randomised controlled trial, patients requiring surveillance colonoscopy were randomised to 
chromoendoscopy or NBI. The dysplasia detection rate was not different between the two groups (21.2% CE 
vs. 21.5% in NBI p0.964), but DCE added an average of 7 minutes to procedure time. (46) (Table 2) 
There are no published data about either the use of  BLI or LCI  to detect colonic lesion in IBD patients. 
Further study in IBD patients are needed to understand if BLI or LCI may be useful in these patients.  
 
(C) Endoscopic characterisation of colonic lesions in IBD 
Accurate endoscopic characterisation of colonic dysplastic lesions is important for therapeutic management. 
Blackstone was the first to describe the morphologic findings of the colonic dysplasia in IBD  as a polypoid 
mass  and a plaque-like lesion (47). SCENIC consensus guidelines introduced the modified Paris classification 
which included border and ulceration of the lesion and replaced the terms dysplasia-associated lesion or mass 
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(DALM) and adenoma-like (ALM) and non–adenoma-like in the non-polypoid and polypoid colorectal 
dysplasia (3) SCENIC did not consider the endoscopic features and characterisation to predict histology and 
invasiveness of the lesions detected at surveillance in IBD patients.  
Recently, Sugimoto et al have classified for the first time the morphologic features of the High Grade 
Dysplasia (HGD) using the SCENIC consensus guidelines. The authors found 84.6% of HGD lesions were 
non-polypoid in appearance (superficial elevated, flat and depressed) and no HGD lesions with Kudo pit 
pattern I or II. Superficial elevated lesions were associated with Kudo pit pattern IV –V gyrus-like villous, and 
flat lesions associated with Kudo pit pattern IIIL-large tubular or roundish using magnification endoscopy 
(48,3).  
Iacucci et al examined the features of neoplastic lesions associated with IBD, and through multivariate 
analysis a neoplastic pit pattern (III-V) (OR 21.5) and location within the right colon (OR 6.52) were 
associated with neoplasia (45).  Also, Carballal et al also investigated features of neoplasia and found that 
lesions in the proximal colon OR 1.86 (1.02-3.40 p0.041), protruding morphology (Is, Ip) OR 2.8 (1.57-5.01 
p0.001), loss in innominate lines OR 1.95 (1.06-3.58 p0.003) and neoplastic pit pattern (III-V) OR 5.05 (2.58-
9.88 p0.001) (38) 
 
Recently, Bisschops  et al assessed the accuracy levels of agreement amongst experts of Kudo pit pattern in 
UC with non-magnified colonoscopy and NBI. Using the Kudo pit pattern, experts differentiated between 
neoplastic and non-neoplastic lesions with a sensitivity of 77%, specificity 68%, NPV 88% and PPV 46%. 
The NPV between DCE and NBI were comparable (p=0.739). The inter-observer agreement was   better with 
DCE (κ 0.332 Vs. 0.224 p=0.001) when using Kudo Pit Patterns. Interobserver aAgreement improved when 
participants were asked to differentiate neoplastic Vs non-neoplastic where NBI performed better than DCE 
(κ 0.653 vs. 0.495 p<0.001). Therefore, the authors found that expert endoscopists have a moderate to 
substantial inter-observer agreement. (49) It is still controversial whether the Kudo pit pattern can be  used to 
predict histology of colonic IBD lesions especially in the presence of inflammation associated regenerative 
pattern and  when assessed by using standard colonoscopes without magnification  in non-experts hands . (50) 
Nevertheless ,the optimal method of assessing the pit pattern  remains still controversial and needs to be 
explored  in future studies ( Figures 1-3) 
 
(D) Therapeutic management of colonic dysplasia in IBD  
 The appropriate management of colonic dysplasia in IBD patients is evolving with advances in endoscopic 
technology and new devices. SCENIC consensus guidelines have also introduced new terminology to describe 
  14
colonic lesions and the new concept of the endoscopic resectability when dysplasia appears circumscribed. 
They also recommend continued post-polypectomy endoscopic surveillance as strategy.(3) Despite limited 
data on endoscopic management of colonic lesions in IBD, endoscopic mucosal resection (EMR) is 
increasingly adopted to remove these lesions. A large retrospective study by Vieth  et al demonstrated 
endoscopic resection of polypoid lesions associated with UC is an adequate treatment alternative to 
proctocolectomy. Following a mean follow up period of 53 months, only 4.6% were found to have further 
methachronous dysplasia. ( figure 3 )However two of the four patients had colitis associated adenocarcinoma 
treated by surgical resection. When comparing outcomes there was no statistical difference between 
polypectomy vs. proctocolectomy. This retrospective suggests endoscopic resection is adequate but careful 
colonoscopy surveillance is vital to exclude further metachronous dysplasia.(51) A meta-analysis by Wanders 
et al on outcomes following endoscopic resection of polypoid lesions in IBD revealed similar results(53). 
Sessile	serrated	adenoma	may	be	locally	resected	at	endoscopy		by	EMR	or	ESD	if	it	meets	SCENIC	
resectability	criteria.	However, EMR does have drawbacks and its limitations. The technique for polypoid 
lesions in general involves removing large lesions, sometimes in piecemeal fashion reducing the chance of 
accurate histological assessment, and has high recurrence rates than ESD (REF).  Endoscopic submucosal 
dissection (ESD) is ideal endoscopic technique that has been proposed to treat colonic IBD dysplastic lesions  
which allow endoscopic resection en bloc, and is associated with much lower recurrence rates. (52) ESD is 
still experimental in IBD due the higher complication risks even in experts hands and long term outcomes  
after lesion removal  is not yet clear. ( Figure 4) 
 
A pilot study by Iacopini et al demonstrated the safety of ESD in nine UC patients, with an excellent curative 
rate of 70%  at 2 years in patients with non-polypoid lesions >20mm. (57) Recently, Suzuki et al have 
confirmed the safety and efficacy of ESD in the IBD population. They reported only 1 recurrence in 32 
dysplastic lesions resected by ESD technique at a median of 33 months of follow up, with only 1 patient 
having delayed bleeding as a complication. However caution should be exercised due to submucosal fibrosis 
from chronic inflammation  which will make the procedure difficult and increase the risk of complications. 
(53,54) 
 
Recently, Kinoshita et al  investigated retrospectively 25 patients with  UC who underwent colonic ESD for 
dysplastic lesions .  It is recommended ESD technique should be performed in expert hands and post-
polypectomy surveillance should be considered. (XXXfigures with ESD) . Therefore, specialised training and 
adequate clinical experience appear to be necessary to acquire a high level of skill for performing ESD. DCE	
and	VCE	may	be	usefully	combined	especially	to	characterise	lesions	and	define	margins	accurately	for	
EMR	and	ESD,	but	this	requires	further	study. In the future we should not be hesitant to implement new 
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colon sparing endoscopic management of colonic dysplastic lesions. (55) 
 
 
5.ENDOSCOPIC TECHNOLOGIES IN EVOLUTION  
 (A) Confocal laser endomicroscopy (CLE)  
CLE is a relatively new technique which allows “in vivo” microscopic evaluation of the colonic mucosa, like  
‘real time histology’ to facilitate diagnosis and  decision regarding resectability of lesions. 
In the past, CLE could be performed with an endoscope-based equipment (Pentax; Tokyo, Japan; iCLE), 
which is no longer clinically available. In more recent studies CLE is performed using a through the scope 
probe (Cellvizio, Mauna Kea ; Paris, France; pCLE). During CLE image acquisition, application of 
fluorescent agents is necessary, either systemic (i.e., fluorescein sodium) or topical (e.g., acriflavine 
hydrochloride, cresyl violet acetate) to highlight cellular, subcellular, and vessel architecture  (56) 
Many studies with CLE have shown its potential in IBD to differentiate between CD and UC, assess grade of  
inflammation , predict outcome and characterise colonic  dysplastic lesions by targeting biopsies  and directing  
endoscopic management . 
 
(i) Assessment of Disease Activity  
Kiesslich et al first described the role of CLE to assess grade of inflammation in UC. They found that the 
endoscopic agreement of extent of inflammation with histological findings was 95.0% versus 34.2% in favour 
of the CLE group (p<0.0001). The agreement with inflammatory activity was 92.5% in CLE group versus 
58.9% in WLE group (p 0.046).(58)  Subsequently  Watanabe et al (57) reported inflammatory activity 
assessment by CLE by grading  the crypt, vessels architecture,  and cellular infiltration.  Li et al assessed the 
inflammatory changes looking at the capillary architecture, the luminal fluorescein leakage and the 
appearance of the crypts (58). Recently Tontini et al developed a new endomicroscopy scoring system to 
differentiate between CD and UC (59,60).  Tontini et al have developed endomicroscopy prognostic factors  
to predict outcome of the disease and risk stratification .   Hundorfean et al have validated a new MH 
endomicrosocpy score which  could accurately assess all inflammatory changes. The new eMHs showed high 
sensitivity, specificity, and accuracy values (100% , 93.75% ;. and 94.44%, respectively).) correlating well 
with the histological Gupta score (rs = 0.82, P < 0.0001 (61) 
 
(ii) Diagnosis of dysplasia  
  16
Studies have explored the use of CLE in the detection of dysplasia in patients with IBD. A first randomised  
CLE study by Kiesslich et al revealed a high diagnostic accuracy to detect dysplastic lesions  when using CLE 
in the setting of UC. They found that 4.75x more neoplasia were detected in the DCE/CLE group  (p=0.005) 
and the accuracy of CLE at predicting histology was 97.8%, sensitivity 94.7% and specificity 98.3% (56).  
Rispo et al further confirmed the accuracy of CLE for the diagnosis of dysplasia in patients with UC. They 
used a combination of DCE and CLE, and had a dysplasia detection rate of 98%, with CLE having a 100% 
sensitivity, (specificity 90%, PPV 83% and NPV 100%) (62) Van den Broek et al evaluated the feasibility and 
accuracy of CLE in UC surveillance.  A sensitivity of 65%, specificity 82% and accuracy of 81% are 
encouraging, but these were much lower than those patients having HD and NBI (100%, 89% and 92% 
respectively) (63). ( Figure 5) 
 
 
(iii) Endoscopic molecular labelling  to stratify patients for therapy 
The concept of tailoring therapy to individual patients based on molecular analysis may play a key role in 
maximising benefits and minimising risks. The potential future use  of molecular  imaging  to  stratify  IBD 
patients regarding response to targeted monoclonal antibody therapies is exciting but challenging. 
Molecular imaging is based on the utilisation of fluorescent probes with specificity toward defined molecular 
targets and their visualisation by endoscopic devices such as CLE. (64, 65) 
The first molecular imaging study has been performed for anti-tumor necrosis factor (anti- TNF) response 
(66). The study assessed the number of mTNF-expressing mucosal cells in Crohn’s disease patients ‘ex vivo’ 
and ‘in vivo’ after topical application of a GMP- fluorescent anti-TNF antibody (fluorescein isothiocyanate-
FITC adalimumab) to the most inflamed area of the mucosa and subsequent imaging by CLE. FITC labelled 
monoclonal antibodies cannot be injected intravenously. There was a significant correlation between 
mucosal mTNF-expression and therapeutic response to subsequent therapy with adalimumab- - patients with 
high amounts of mTNF expressing  cells had a significantly  higher  probability  of  responding  to  anti-
TNF  therapy  at  week  12  (92%) compared with patients with low amounts of mTNF expressing cells 
(15%). The sensitivity and specificity for prediction were 92% and 85%, respectively. (64) Recently , 
molecular methods has been also been used to determine the response to vedolizumab in IBD patients by 
evaluating the α4β7 integrin expression  (65) or to detect dysplasia in UC patients ( 66) 
Molecular endoscopic imaging is an exiting but still a research field and will not be adopted into clinical 
routine without extensive validation.  
(B) Endocytoscopy  
Endocytoscopy (EC) is a ‘super’ high-resolution endoscopic technique that enables the real-time observation 
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of cells and nuclei of mucosal surfaces during ongoing endoscopy in vivo with magnification ranging from 
450- to 1400-fold – it permits prediction of histology and direct sampling virtual biopsy  Recently a new 
endocytoscopy system (GIF-Y0002), using only one lens, was introduced; it allows continuous increase of 
zooming power from the conventional endoscopy level, up to 380-fold. Endocytoscopy requires absorptive 
staining agents, like methylene blue, toluidine blue or cresyl violet sprayed onto the mucosa and mucolysis 
with N-acetylcysteine.  
Bessho et al developed a score for UC assessment using EC termed The Endocystocopy System Score (ECSS), 
which included: A. shape of crypts; B. distance between neighbouring crypts; and C. visibility of superficial 
microvessels. For the total score good agreement between endoscopists was demonstrated k = 0.79 (95% CI 
0.71-0.87 p<0.001). It also showed a strong correlation with histopathological grades for disease activity, 
(r=0.713 p<0.001) (67).  In a small study of 40 patients with IBD the concordance between EC and histology 
was 100%. (68)  A further study aimed to identify the usefulness of endocystoscopy to assess MH in patients 
with UC  with MES 0/1, and showed that ECSS correlated well with histology. They also demonstrated 
features that showed high degree of inflammatory cell infiltrates and therefore could predict relapse (69).  
Clinical application is limited by the high cost compared with traditional histological techniques.  It requires 
training and determination of learning curve before deciding on potential clinical application. ( figure 6) 
 
 
5.ENDOSCOPIC TECHNOLOGIES IN EVOLUTION  
 (A) Confocal laser endomicroscopy (CLE)  
CLE is a relatively new technique which allows “in vivo” microscopic evaluation of the colonic mucosa, like  
‘real time histology’ to facilitate diagnosis and  decision regarding resectability of lesions. 
In the past, CLE could be performed with an endoscope-based equipment (Pentax; Tokyo, Japan; iCLE), 
which is no longer clinically available. In more recent studies CLE is performed using a through the scope 
probe (Cellvizio, Mauna Kea ; Paris, France; pCLE). During CLE image acquisition, application of 
fluorescent agents is necessary, either systemic (i.e., fluorescein sodium) or topical (e.g., acriflavine 
hydrochloride, cresyl violet acetate) to highlight cellular, subcellular, and vessel architecture  (56) 
Many studies with CLE have shown its potential in IBD to differentiate between CD and UC, assess grade of  
inflammation , predict outcome and characterise colonic  dysplastic lesions by targeting biopsies  and directing  
endoscopic management . 
 
(i) Assessment of Disease Activity  
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Kiesslich et al first described the role of CLE to assess grade of inflammation in UC. They found that the 
endoscopic agreement of extent of inflammation with histological findings was 95.0% versus 34.2% in favour 
of the CLE group (p<0.0001). The agreement with inflammatory activity was 92.5% in CLE group versus 
58.9% in WLE group (p 0.046).(58)  Subsequently  Watanabe et al (57) reported inflammatory activity 
assessment by CLE by grading  the crypt, vessels architecture,  and cellular infiltration.  Li et al assessed the 
inflammatory changes looking at the capillary architecture, the luminal fluorescein leakage and the 
appearance of the crypts (58). Recently Tontini et al developed a new endomicroscopy scoring system to 
differentiate between CD and UC (59,60).  Tontini et al have developed endomicroscopy prognostic factors  
to predict outcome of the disease and risk stratification .   Hundorfean et al have validated a new MH 
endomicrosocpy score which  could accurately assess all inflammatory changes. The new eMHs showed high 
sensitivity, specificity, and accuracy values (100% , 93.75% ;. and 94.44%, respectively).) correlating well 
with the histological Gupta score (rs = 0.82, P < 0.0001 (61) 
 
(ii) Diagnosis of dysplasia  
Studies have explored the use of CLE in the detection of dysplasia in patients with IBD. A first randomised  
CLE study by Kiesslich et al revealed a high diagnostic accuracy to detect dysplastic lesions  when using CLE 
in the setting of UC. They found that 4.75x more neoplasia were detected in the DCE/CLE group  (p=0.005) 
and the accuracy of CLE at predicting histology was 97.8%, sensitivity 94.7% and specificity 98.3% (56).  
Rispo et al further confirmed the accuracy of CLE for the diagnosis of dysplasia in patients with UC. They 
used a combination of DCE and CLE, and had a dysplasia detection rate of 98%, with CLE having a 100% 
sensitivity, (specificity 90%, PPV 83% and NPV 100%) (62) Van den Broek et al evaluated the feasibility and 
accuracy of CLE in UC surveillance.  A sensitivity of 65%, specificity 82% and accuracy of 81% are 
encouraging, but these were much lower than those patients having HD and NBI (100%, 89% and 92% 
respectively) (63). ( Figure 5) 
 
 
(iii) Endoscopic molecular labelling  to stratify patients for therapy 
The concept of tailoring therapy to individual patients based on molecular analysis may play a key role in 
maximising benefits and minimising risks. The potential future use  of molecular  imaging  to  stratify  IBD 
patients regarding response to targeted monoclonal antibody therapies is exciting but challenging. 
Molecular imaging is based on the utilisation of fluorescent probes with specificity toward defined molecular 
targets and their visualisation by endoscopic devices such as CLE. (64, 65) 
  19
The first molecular imaging study has been performed for anti-tumor necrosis factor (anti- TNF) response 
(66). The study assessed the number of mTNF-expressing mucosal cells in Crohn’s disease patients ‘ex vivo’ 
and ‘in vivo’ after topical application of a GMP- fluorescent anti-TNF antibody (fluorescein isothiocyanate-
adalimumab) to the most inflamed area of the mucosa and subsequent imaging by CLE. There was a 
significant correlation between mucosal mTNF-expression and therapeutic response to subsequent therapy 
with adalimumab- - patients with high amounts of mTNFfl cells had a significantly  higher  probability  of  
responding  to  anti-TNF  therapy  at  week  12  (92%) compared with patients with low amounts of 
mTNFfl cells (15%). The sensitivity and specificity for prediction were 92% and 85%, respectively. (64) 
Recently , molecular methods has been also been used to determine the response to vedolizumab in IBD 
patients by evaluating the α4β7 integrin expression  (65) or to detect dysplasia in UC patients ( 66) 
Molecular endoscopic imaging is an exiting but still a research field and will not be adopted into clinical 
routine without extensive validation.  
(B) Endocytoscopy  
Endocytoscopy (EC) is a ‘super’ high-resolution endoscopic technique that enables the real-time observation 
of cells and nuclei of mucosal surfaces during ongoing endoscopy in vivo with magnification ranging from 
450- to 1400-fold – it permits prediction of histology and direct sampling virtual biopsy  Recently a new 
endocytoscopy system (GIF-Y0002), using only one lens, was introduced; it allows continuous increase of 
zooming power from the conventional endoscopy level, up to 380-fold. Endocytoscopy requires absorptive 
staining agents, like methylene blue, toluidine blue or cresyl violet sprayed onto the mucosa and mucolysis 
with N-acetylcysteine.  
Bessho et al developed a score for UC assessment using EC termed The Endocystocopy System Score (ECSS), 
which included: A. shape of crypts; B. distance between neighbouring crypts; and C. visibility of superficial 
microvessels. For the total score good agreement between endoscopists was demonstrated k = 0.79 (95% CI 
0.71-0.87 p<0.001). It also showed a strong correlation with histopathological grades for disease activity, 
(r=0.713 p<0.001) (67).  In a small study of 40 patients with IBD the concordance between EC and histology 
was 100%. (68)  A further study aimed to identify the usefulness of endocystoscopy to assess MH in patients 
with UC  with MES 0/1, and showed that ECSS correlated well with histology. They also demonstrated 
features that showed high degree of inflammatory cell infiltrates and therefore could predict relapse (69).  
Clinical application is limited by the high cost compared with traditional histological techniques.  It requires 
training and determination of learning curve before deciding on potential clinical application. ( figure 6) 
 
6. FUTURE DIRECTION AND CONCLUSIONS  
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The techniques of defining the mucosa in details at endoscopy are rapidly evolving and dynamic. There are 
various endoscopic systems that have been developed and introduced in clinical practice and in research and 
more are in development.  The advances in optical technology in endoscopes have resulted in brighter and 
higher resolution images thus describing better endoscopic mucosal and vascular features in IBD, as well as 
lesion characterisation features in dysplasia .  It may now enable us to define the intestinal surface in details 
that may approximate histology. WLE descriptive terms such as loss of vascular pattern and friability may 
now be replaced with more precise terminology of vascular patterns 
New VCE scoring systems using the new generation of colonocopes with and without magnification have 
been developed and endoscopic findings of MH have been described which correlate well with  histological 
healing.  All gastroenterologists should become familiar with the use of electronic chromoendoscopy as these 
are now integrated in all equipment. Further prospective studies are ongoing to evaluate how these 
technologies may impact on clinical practice in real life. Randomised studies using VCE or HD images have 
shown non inferior detection rate of dysplasia comparing with DCE as standard of practice  during 
surveillance colonoscopy in patients with IBD. If further and larger studies further corroborate these findings, 
dyeless surveillance colonoscopy may gain a place in clinical practice. In addition, more precise lesion 
characterisation at surveillance colonoscopy harnessing new refined technologies are permitting local 
resections in selected lesions rather than pan-proctocolectomy.  
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Figures Legends: 
 
 
Figure 1: a) High definition  b-c)Iscan Optical enhancement ( Pentax Japan) with and without magnification 
showed a low grade dysplastic  sessile lesion with Kudo pit pattern  IIIL-IV and regular margin 
 
Figure 2: a) DCE b-c) NBI ( Olympus  Japan) showed a low grade dysplastic  sessile lesion with  mixed Kudo 
pit pattern II0  IIIL-IV and regular margin . 
 
Figure 3: a) DCE b-c) LCI(Fujifilm ,Japan) showed a low grade dysplastic  sessile lesion with  Kudo pit 
pattern IIIL and regular margin .D) cautery snared polypectomy  
 
 
Figure 4: a-c)  HD and DCE showed flat depressed colonic lesion Paris Iib+IIC  d-e ) NBI with magnification 
revealed Kudo pit pattern type IV-V  f-i) ESD technique with dual Knife  . The lesion was successfully 
resected en-bloc without perforation Histology reported tubular adenocarcioma T1b(SMI. 300 umm ) 
Negative tumor margins ESD was curative  
 
Figure 5:A-b) VCE –iSCAN ( pentax Japan) and DCE with methylene blue 1%  showed flat  dysplastic lesion 
Paris classification type IIB with irregular margins c ) pCLE showed villiform  and irregular crypts with dark 
epithelium d)  Histology with H&E confirmed LGD –DALM 
 
Figure 6: a –b )  HD and DCE showed  colonic  flat elevated dysplastic lesions , Paris IIa+Iib  with irregular 
margins . c ) Endocytoscopic image (orig. mag.450) after methylene blue dye stain showed nuclei of epithelial 
cells are much more strongly stained suggesting cellular dysplasia   d) Image (H&E, orig. mag. 400).  
Confirmed diagnosis  of well –differentiated adenocarcinoma  Courtesy of Center for Diagnostic and 
Therapeutic Endoscopy, School of Medicine, Keio University, Japan 
 
 
 
 
	
	
Endoscopic scores  Endoscopic 
Technique 
Endoscopic 
Findings 
Validation Pro Cons 
Table	1.	Endoscopic	scoring	systems	in	UC	using	WLE	and	VCE		
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Mayo Endoscopy 
subscore [11] 
(1987) 
 
 
WLE 
Vascular pattern, 
erythema, friability, 
erosions and 
ulceration, bleeding 
 
Partially 
validated 
Easy to use ,
Widely used in 
clinical trials 
No endoscopic definition of MH 
Overlap grade 1–2;subjective 
elements 
 
 
Ulcerative Colitis 
Endoscopic Index of 
Severity (UCEIS)[12] 
(2012) 
 
 
 
 
WLE 
Vascular pattern (3 
levels), bleeding (4 
levels), ulceration 
(4 levels) 
 
 
Validated 
 
 
Easy to use;  
Closely 
correlated 
with clinical 
activity. 
Validated  
No endoscopic definition of MH; 
No thresholds for mild, 
moderateand severe disease; 
No Definition of superficial vs. 
deep ulcer 
 
Ulcerative Colitis 
Colonoscopic Index 
of Severity 
(UCCIS)[13] 
(2013) 
 
 
 
WLE 
Vascular pattern, 
granularity, lesions, 
Friability/bleeding 
Partially 
validated   Easy to use  
 Partially 
Validated 
Requires total colonoscopy;No 
definition of MH; No thresholds 
for mild, moderate and severe 
disease. Developed in a single 
centre  
 
Modified Mayo 
Endoscopic score 
(MMS)[18] 
(2015) 
WLE  Vascular pattern, 
granularity, 
friability, bleeding, 
ulceration 
 
Not
Validated  
Easy to use 
Significant 
correlation 
with clinical 
activity 
No established thresholds for mild, 
moderate and severe disease  
 a
Magnifying 
Colonoscopy UC 
grade [27] 
(2006) 
NBI 
+magnification  
Grade 1: pits small, 
round and regularly 
arranged Grade 2: 
pits rather large, 
oval and somewhat 
irregular in 
arrangement Grade 
3: pits of various 
shapes and sizes 
and irregularly 
arranged Grade 4: 
dispersed pits 
varying in 
morphology, 
associated with the 
presence of small 
erosioln 
 
Not
Validated    
Endoscopic 
Definition of 
MH 
 
Difficult to be adopted in clinical 
practice . Required  advanced 
endoscopic technologies and 
expertise . No threshold of 
different grade of inflammation  
Paddington  VCE‐iSCAN  See table 2  Partially  Definition of 
mucosal and 
Requires endoscopy experience 
No threshold for different levels 
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Table 2. The PICaSSO ( Paddinghton International Virtual Chromoendosocpy Score ) in Ulcerative 
Colitis  
 
 
 
 
 
 
International Virtual 
ChromoendoScopy 
ScOre (PICaSSO )[19] 
(2017) 
Validated vascular MH; 
Correlate with 
histological 
healing 
of inflammation and healing. 
No clinical outcome  
Mad 
Linked Colour 
Imaging [32] 
(2017) 
LASEREO 
LCI 
LCI  vascular patterns 
A, no redness; B, 
redness with visible 
vessels; and C,redness 
without visible 
vessels 
No validated  Definition of 
Vascular 
Healing  
Endoscopic 
Definition of 
MH 
 
Difficult to be adopted in clinical 
practice. Required  advanced 
endoscopic technologies and 
expertise . No mucosal pattern 
evaluation. 
Mucosal	architecture	
0)	No	mucosal	defect	
a) Continuous/regular	crypts	
b) Crypts	not	visible	(scar)	
c) Discontinuous	and	or	
dilated/elongated	crypts	
I) Micro‐erosions	/	crypt	abscess		
1)	Discrete	
2)	Patchy	
3)	Diffuse	
II)	Erosions	size	<5	mm	
1	–	3)	As	above	
Vascular	architecture	
0)	Vessels;	no	dilatation	
a) Roundish	following	crypts	
b) Vessels	not	visible	(scar)	
c) Sparse	(deep)	vessels	
	
I) Vessels;	with	dilatation		
a) Roundish		
b) Crowded	/	tortuous	superficial	vessels	
		
II)	Intramucosal	bleeding		
III)	Luminal	bleeding		
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Table 3: Detection rate of dysplasia  in studies comparing DCE vs VCE or HD. 
DCE vs WLE or HD 
Study  Year  Type of study  Type of endoscopy N of pts Dysplasia
      DCE WLE  HD 
Kiesslich et al[33]  2003  Randomised  DCE vs WLE 165 35 11  
Rutter et al[35]  2004  Non‐randomised  DCE vs WLE 100 9 2  
Marion et al[36]  2008  Non‐randomised  DCE vs WLE 102 22 16  
Picco et al[37]  2013  Non‐randomised  DCE vs WLE 75 22 10  
Carballal et al[38]  2018  Non‐randomised  DCE vs WLE vs HD 350 94 27 31 
NBI vs WLE or HD 
Study  Year  Type of study  Type of endoscopy N of pts Dysplasia
      NBI WLE or HD 
Dekker et al[39]  2007  Non‐randomised  NBI vs WLE 42 9 13
Van den Broek et al[40]  2011  Non‐randomised  NBI vs HD 48 13 11
Ignjatovic et al[42]  2012  Randomised  NBI vs WLE 112 5 7
Leifeld et al[43]  2015    NBI vs HD 159 31 30
NBI vs DCE 
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Study  Year  Type of study  Type of endoscopy N of pts Dysplasia
      NBI DCE
Pellise’ et al[41]  2011  Randomised  DCE vs         NBI vs DCE  60  10  12 
Bisschops et al[46]  2018  Randomised  NBIDCE vs DCENBI 131 22 31
Efthymiou et al[44]  2013  Non‐randomised  NBIDCE vs DCENBI 44 23 27
iSCAN vs DCE 
Study  Year  Type of study  Type of endoscopy N of pts Dysplasia
      iSCAN DCE HD 
Iacucci et al[45]  2018  Randomised  iSCANHD vs DCE vs HDiSCAN  270  23  27  42 
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